Autopsy report · NCT02179567

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

“Terminated due to poor accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 years 3 months after it had already started.
• Ran for about 3 years before it stopped.
• 26 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hellenic Oncology Research Group

Sponsor type

University, hospital or other

Conditions

NSCLC

Interventions

Docetaxel; Bevacizumab

Participants

26

Sites

5

Countries

Greece

Trials that died the same way

• A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain
  “Terminated due to low accrual” (95% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (89% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (86% match in meaning)
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
  “Terminated due to slow accrual” (86% match in meaning)
• A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
  “Terminated prior to completion of accrual per corporate decision.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.